Skip to main
PLRX
PLRX logo

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics is focused on advancing its lead product candidate, bexotegrast, a small molecule targeting integrins αvβ8 and αvβ1, which has shown signs of efficacy in treating idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The company is preparing to initiate a new Phase 2b dose-ranging study for bexotegrast in IPF, with the potential to optimize the drug's risk-benefit profile through targeted therapy that enhances safety. Given the encouraging preliminary data and the strategic approach to clinical development, Pliant Therapeutics presents a positive outlook for investors as it seeks to establish a strong market position within fibrosis treatment.

Bears say

Pliant Therapeutics has faced a significant setback with the discontinuation of the BEACON-IPF Phase 2b trial for its primary candidate, bexotegrast, due to a safety-related imbalance characterized by unexpectedly low adverse event rates in the placebo group. This interruption not only raises concerns regarding the long-term viability of bexotegrast for idiopathic pulmonary fibrosis but also highlights the company’s reliance on a thin pipeline, which lacks alternative therapeutic options for at least one year. Financially, Pliant reported a substantial net loss of $49.7 million for Q4 2024, further complicating its outlook amid the challenges with product development and limited prospects for advancing its drug candidates.

PLRX has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Buy based on their latest research and market trends.

According to 15 analysts, PLRX has a Buy consensus rating as of Jul 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.